A dual‐bioresponsive drug‐delivery depot for combination of epigenetic modulation and immune checkpoint blockade

H Ruan, Q Hu, D Wen, Q Chen, G Chen… - Advanced …, 2019 - Wiley Online Library
Patients with advanced melanoma that is of low tumor‐associated antigen (TAA) expression
often respond poorly to PD‐1/PD‐L1 blockade therapy. Epigenetic modulators, such as …
被引用次数：181 相关文章

A Dual‑Bioresponsive Drug‑Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade

H Ruan, Q Hu, D Wen, Q Chen, G Chen… - Advanced …, 2019 - ui.adsabs.harvard.edu
Patients with advanced melanoma that is of low tumor‑associated antigen (TAA) expression
often respond poorly to PD‑1/PD‑L1 blockade therapy. Epigenetic modulators, such as …

A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade.

H Ruan, Q Hu, D Wen, Q Chen, G Chen… - … (Deerfield Beach, Fla …, 2019 - europepmc.org
Patients with advanced melanoma that is of low tumor-associated antigen (TAA) expression
often respond poorly to PD-1/PD-L1 blockade therapy. Epigenetic modulators, such as …

A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade

H Ruan, Q Hu, D Wen, Q Chen… - Advanced …, 2019 - providence.elsevierpure.com
Patients with advanced melanoma that is of low tumor-associated antigen (TAA) expression
often respond poorly to PD-1/PD-L1 blockade therapy. Epigenetic modulators, such as …

A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade

H Ruan, Q Hu, D Wen, Q Chen… - Advanced …, 2019 - pubmed.ncbi.nlm.nih.gov
Patients with advanced melanoma that is of low tumor-associated antigen (TAA) expression
often respond poorly to PD-1/PD-L1 blockade therapy. Epigenetic modulators, such as …